Linezolid versus vancomycin for skin and soft tissue infections

Area of Science:

• Infectious Diseases
• Pharmacology
• Clinical Medicine

Background:

• Skin and soft tissue infections (SSTIs) present a significant morbidity and treatment cost burden.
• Linezolid and vancomycin are key antibiotics for treating SSTIs, particularly those caused by methicillin-resistant Staphylococcus aureus (MRSA).

Purpose of the Study:

• To compare the efficacy and safety of linezolid versus vancomycin in treating patients with SSTIs.
• To evaluate outcomes including clinical cure, microbiological cure, and mortality rates.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials (RCTs).
• Included nine RCTs with 3144 participants comparing linezolid and vancomycin for SSTI treatment.
• Primary outcomes: clinical cure, microbiological cure, SSTI-related and treatment-related mortality; subgroup analyses by age and MRSA presence.

Main Results:

• Linezolid showed significantly higher clinical and microbiological cure rates in adults, especially for MRSA infections.
• No significant difference in all-cause mortality; linezolid had fewer instances of red man syndrome, pruritus, and rash.
• Linezolid use was associated with shorter hospital stays and lower overall treatment costs despite higher daily drug costs.

Conclusions:

• Linezolid appears more effective than vancomycin for SSTIs, including MRSA infections.
• Current evidence carries a high risk of bias, with studies funded by the linezolid manufacturer.
• Further well-designed, independently funded RCTs are necessary to validate these findings.